Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 8 Midostaurin lowers blood pressure in SHR and WKY, but not in L-NAME–treated WKY. Systolic and diastolic blood pressure (SBP, DBP) was measured telemetrically in conscious rats with implanted transmitter-coupled pressure transducers. (A) Spontaneously hypertensive rats were first treated orally with vehicle for 1 week. After recovery for another week, rats were treated orally with midostaurin (Mido, 75 mg/kg/day) for 7 days. Arrows indicate the single doses. Symbols represent mean ± SEM of three experiments of six rats each. (B) Wistar-Kyoto rats were treated orally with midostaurin (Mido, 75 mg/kg/day) for 7 days. Symbols represent mean ± SEM of nine rats. (C) Wistar-Kyoto rats were treated with the NOS inhibitor L-NAME (24 mg/kg/day, in the drinking water) from day 2 through day 7. Midostaurin (Mido, 75mg/kg/day) was administrated orally from day 4 through day 7. Symbols represent mean ± SEM of 9 rats. (*p < 0.05, **p < 0.01 ***p < 0.001, compared with the value before midostaurin treatment, tested by ANOVA followed by Fisher protected least-significant-difference test.) Abbreviations as in Figure 1.
|
